Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a stable, long-term form of heart failure where the heart's pumping function is reduced, along with reduced kidney function (as measured by a specific kidney test result below a certain level)
- People whose heart failure symptoms are moderate — meaning they have some limitations during physical activity but are comfortable at rest (this is referred to as NYHA class II or III, confirm with trial site)
- People who are assessed as low risk when doing physical exercise (as determined by a medical assessment)
- People aged between 18 and 75 years
Who may not be able to join:
- People with high blood pressure that is not well controlled
- People with serious heart rhythm problems, including certain types of irregular heartbeats, abnormally fast heart rhythms, or problems with the heart's electrical signalling system
- People with a type of thickened heart muscle condition that blocks blood flow out of the heart
- People with moderate to severe narrowing of one or more heart valves
- People with a blood clot in a deep vein or in the lungs
- People who have a history of fainting episodes
- People with severely low red blood cell levels
- People with thyroid function that is outside the normal range
- People with serious lung conditions
- People with mental illness
- People with bone, joint, or muscle problems that would prevent them from taking part in physical rehabilitation exercises
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference in VO₂ peak (a marker of cardiopulmonary exercise tolerance) between the two groups before and after 6 months of treatment; Difference in 6-minute walk test (6MWT) distance (a marker of cardiopulmonary exercise tolerance) between the two groups before and after 6 months of treatment; Differences in estimated Glomerular Filtration Rate (eGFR) between the two groups before and after 6 months of treatment; Difference in Serum Creatinine (Scr) between the two groups before and after 6 months of treatment; Difference in Left Ventricular Ejection Fraction (LVEF) between the two groups bef...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.